EurekaMag.com logo
+ Site Statistics
References:
53,214,146
Abstracts:
29,074,682
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action


Arzneimittel-Forschung 37(1): 14-16
Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action
In experiments on 6 mongrel dogs the electrophysiologic effects of the new antiarrhythmic compound (.+-.)-6,7,8,9-tetrahydro-2,12-dimethoxy-7-methyl-6-phenethyl-5H-dibenz[d,f]azonin-1-ol (asocainol) were examined in the non-ischemic heart. The PR interval increased significantly following doses of 5 mg/kg caused by a conduction delay in the His-Purkinje system. At high doses (10 mg/kg) the QRS duration was also prolonged. Atrial and ventricular effective refractory periods were only slightly increased. Asocainol significantly increased the atrial fibrillation threshold, whereas the ventricular fibrillation threshold was not altered. Hemodynamics were not changed except for a slight increase in heart rate after 10 mg/kg asocainol. Thus asocainol predominantly exhibited class Ia antiarrhythmic properties, whereas calcium antagonistic actions could not be established in this intact dog heart model.

(PDF 0-2 workdays service: $29.90)

Accession: 005349288

PMID: 3566851



Related references

Antiarrhythmic and electrophysiologic effects of MDL 11,939, a novel class III antiarrhythmic agent in anesthetized dogs. Journal of Cardiovascular Pharmacology 16(3): 383-393, 1990

Electrophysiologic antiarrhythmic and hemodynamic effects of e 4031 a novel class iii antiarrhythmic agent in intact and infarcted dogs. European Heart Journal 9(ABSTR SUPPL 1): 232, 1988

Cardiac electrophysiologic effects of wy 48986 a novel class iii antiarrhythmic agent. Journal of Molecular & Cellular Cardiology 21(SUPPL 2): S20, 1989

Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent. Kokyu to Junkan. Respiration & Circulation 36(10): 1119-1124, 1988

Electrophysiologic effects of E-4031, a new class III antiarrhythmic agent, in patients with supraventricular tachyarrhythmias. American Journal of Cardiology 71(16): 1464-1467, 1993

Frequency dependent electrophysiologic effects of sematilide a pure class iii antiarrhythmic agent. Circulation 84(4 SUPPL 2): II350, 1991

Electrophysiologic effects of Org 7797, a new steroidal antiarrhythmic agent: comparison with class 1a, 1b, and 1c drugs. Journal of Cardiovascular Pharmacology 14(2): 205-212, 1989

Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle. Japanese Heart Journal 39(3): 297-305, 1998

Electrophysiologic and antiarrhythmic effects of the nibentan, a new class III agent, in patients with paroxysmal tachyarrhythmias. European Heart Journal 17(ABSTR SUPPL ): 389, 1996

Electrophysiologic activity and antiarrhythmic efficacy of CK-3579, a new class III antiarrhythmic agent with beta-adrenergic blocking properties. Journal of Cardiovascular Pharmacology 21(4): 647-655, 1993